Charles Schwab Investment Management Inc. Has $38.10 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Charles Schwab Investment Management Inc. lifted its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 243,170 shares of the company’s stock after acquiring an additional 2,954 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Krystal Biotech were worth $38,095,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Entropy Technologies LP acquired a new position in shares of Krystal Biotech in the 4th quarter valued at $548,000. Summit Trail Advisors LLC acquired a new position in Krystal Biotech in the third quarter worth about $1,893,000. Swiss National Bank raised its holdings in shares of Krystal Biotech by 8.0% in the 3rd quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after buying an additional 2,900 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Krystal Biotech by 42.0% in the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock worth $8,239,000 after buying an additional 15,545 shares in the last quarter. Finally, Citigroup Inc. raised its holdings in shares of Krystal Biotech by 65.4% in the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock worth $6,386,000 after buying an additional 13,874 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

KRYS opened at $179.38 on Friday. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34. The company has a fifty day moving average price of $163.50 and a two-hundred day moving average price of $173.90. The firm has a market capitalization of $5.17 billion, a PE ratio of 59.99 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same period last year, the firm posted $0.30 earnings per share. The business’s quarterly revenue was up 116.4% compared to the same quarter last year. Equities analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analysts Set New Price Targets

KRYS has been the subject of several recent analyst reports. Chardan Capital increased their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Jefferies Financial Group started coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Friday, February 28th. Citigroup raised their target price on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Krystal Biotech presently has an average rating of “Buy” and an average price target of $220.00.

Insiders Place Their Bets

In related news, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).